Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick C Ma

Showing results (31-40 of 85) with videos related to

Pageof 9
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 2, 2014
RET-rearranged lung adenocarcinomas with lymphangitic spread, psammoma bodies, and clinical responses to cabozantinibSanjay Mukhopadhyay, Nathan A Pennell, Siraj M Ali, et al.
Cancers|March 6, 2021
Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?Heidar J Albandar, Jacob Fuqua, Jasim M Albandar, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 20, 2012
Phase-II trial of rebeccamycin analog, a dual topoisomerase-I and -II inhibitor, in relapsed "sensitive" small cell lung cancerAnita Schwandt, Tarek Mekhail, Balazs Halmos, et al.
Clinical Chemistry|March 9, 2010
Quantifying EGFR alterations in the lung cancer genome with nanofluidic digital PCR arraysJun Wang, Ramesh Ramakrishnan, Zhe Tang, et al.
Clinical Lung Cancer|February 20, 2021
A Prospective Trial Evaluating the Safety and Systemic Response From the Concurrent Use of Radiation Therapy with Checkpoint Inhibitor Immunotherapy in Metastatic Non-Small Cell Lung CancerMalcolm D Mattes, Timothy D Eubank, Mohammed Almubarak, et al.
BMC Health Services Research|April 10, 2022
Utilization and costs of epidermal growth factor receptor mutation testing and targeted therapy in Medicare patients with metastatic lung adenocarcinomaChan Shen, Rolfy A Perez Holguin, Eric Schaefer, et al.
Cancer Research|October 16, 2003
c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functionsPatrick C Ma, Takashi Kijima, Gautam Maulik, et al.
Cancers|September 14, 2024
Sex Difference in Disease-Related Adverse Events Post-Diagnosis of Lung Cancer Brain Metastases in Medicare Individuals ≥ 66 Years of AgeMantas Dmukauskas, Gino Cioffi, Kristin A Waite, et al.
JCO Precision Oncology|April 5, 2024
Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With <i>KRAS</i><sup>G12C</sup>-Mutated Non-Small Cell Lung Cancer: A Case Series and Literature ReviewJia Luo, Narjust Florez, Anjali Donnelly, et al.
Journal of Medicinal Chemistry|December 9, 2009
In vivo positron emission tomography (PET) imaging of mesenchymal-epithelial transition (MET) receptorChunying Wu, Zhe Tang, Weiwen Fan, et al.
Pageof 9

Showing results (31-40 of 85) with videos related to

Sort By:
Pageof 9
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 2, 2014
RET-rearranged lung adenocarcinomas with lymphangitic spread, psammoma bodies, and clinical responses to cabozantinibSanjay Mukhopadhyay, Nathan A Pennell, Siraj M Ali, et al.
Cancers|March 6, 2021
Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?Heidar J Albandar, Jacob Fuqua, Jasim M Albandar, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 20, 2012
Phase-II trial of rebeccamycin analog, a dual topoisomerase-I and -II inhibitor, in relapsed "sensitive" small cell lung cancerAnita Schwandt, Tarek Mekhail, Balazs Halmos, et al.
Clinical Chemistry|March 9, 2010
Quantifying EGFR alterations in the lung cancer genome with nanofluidic digital PCR arraysJun Wang, Ramesh Ramakrishnan, Zhe Tang, et al.
Clinical Lung Cancer|February 20, 2021
A Prospective Trial Evaluating the Safety and Systemic Response From the Concurrent Use of Radiation Therapy with Checkpoint Inhibitor Immunotherapy in Metastatic Non-Small Cell Lung CancerMalcolm D Mattes, Timothy D Eubank, Mohammed Almubarak, et al.
BMC Health Services Research|April 10, 2022
Utilization and costs of epidermal growth factor receptor mutation testing and targeted therapy in Medicare patients with metastatic lung adenocarcinomaChan Shen, Rolfy A Perez Holguin, Eric Schaefer, et al.
Cancer Research|October 16, 2003
c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functionsPatrick C Ma, Takashi Kijima, Gautam Maulik, et al.
Cancers|September 14, 2024
Sex Difference in Disease-Related Adverse Events Post-Diagnosis of Lung Cancer Brain Metastases in Medicare Individuals ≥ 66 Years of AgeMantas Dmukauskas, Gino Cioffi, Kristin A Waite, et al.
JCO Precision Oncology|April 5, 2024
Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With <i>KRAS</i><sup>G12C</sup>-Mutated Non-Small Cell Lung Cancer: A Case Series and Literature ReviewJia Luo, Narjust Florez, Anjali Donnelly, et al.
Journal of Medicinal Chemistry|December 9, 2009
In vivo positron emission tomography (PET) imaging of mesenchymal-epithelial transition (MET) receptorChunying Wu, Zhe Tang, Weiwen Fan, et al.
Pageof 9